Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot Study
<i>Background and Objectives</i>: congenital heart disease (CHD), cyanotic and, to a lesser degree, acyanotic, often are accompanied by coagulation abnormalities, impacting substantially morbidity and mortality. Until now, no consistent hemostatic patterns have been demonstrated in neona...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/60/2/268 |
| _version_ | 1827343215066349568 |
|---|---|
| author | Paraskevi Papadogeorgou Serena Valsami Maria Boutsikou Eleni Pergantou Aimilia Mantzou Ioannis Papassotiriou Zoi Iliodromiti Rozeta Sokou Elena Bouza Marianna Politou Nicoletta Iacovidou Theodora Boutsikou |
| author_facet | Paraskevi Papadogeorgou Serena Valsami Maria Boutsikou Eleni Pergantou Aimilia Mantzou Ioannis Papassotiriou Zoi Iliodromiti Rozeta Sokou Elena Bouza Marianna Politou Nicoletta Iacovidou Theodora Boutsikou |
| author_sort | Paraskevi Papadogeorgou |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: congenital heart disease (CHD), cyanotic and, to a lesser degree, acyanotic, often are accompanied by coagulation abnormalities, impacting substantially morbidity and mortality. Until now, no consistent hemostatic patterns have been demonstrated in neonates and children with CHD because they represent a variable and heterogenous population. The aim of the present study is to investigate the hemostatic profile, as well as the role of ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin type-1 motives), the cleaving protein of von Willebrand factor (VWF) in neonates with CHD and compare them to healthy age-matched controls. <i>Materials and Methods</i>: twenty neonates with a mean gestational age of 37.1 ± 2.5 weeks were included in the CHD group, and 18 healthy neonates with a mean gestational age of 38.2 ± 1.5 weeks were in the control group. <i>Results:</i> prothrombin time was significantly prolonged, and accordingly, factor VII (FVII) levels were significantly decreased in the CHD group in comparison to controls. Factor VIII (FVIII), VWF, and ristocetin cofactor activity (Rcof) levels were significantly higher in the study vs. control group. Concentrations of ADAMTS-13 were decreased in the CHD vs. control group, but the difference was not statistically significant. Our results, in combination, indicate a balanced hemostatic mechanism, although with greater variability in neonates with CHD, while developmental aspects of coagulation are evident in the specific patient population. <i>Conclusions:</i> the coagulation profile is moderately impaired early in the course of CHD, though increased thrombogenicity is already present and should not be ignored. |
| first_indexed | 2024-03-07T22:22:00Z |
| format | Article |
| id | doaj.art-9f6f61329d434169a7c3f4f3ff54d159 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-07T22:22:00Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-9f6f61329d434169a7c3f4f3ff54d1592024-02-23T15:26:36ZengMDPI AGMedicina1010-660X1648-91442024-02-0160226810.3390/medicina60020268Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot StudyParaskevi Papadogeorgou0Serena Valsami1Maria Boutsikou2Eleni Pergantou3Aimilia Mantzou4Ioannis Papassotiriou5Zoi Iliodromiti6Rozeta Sokou7Elena Bouza8Marianna Politou9Nicoletta Iacovidou10Theodora Boutsikou11Neonatal Department, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, GreeceBlood Transfusion Department, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, GreeceNeonatal Department, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, GreeceHaemostasis Unit/Haemophilia Centre, “Aghia Sophia” Children’s Hospital, 115 27 Athens, GreeceFirst Department of Paediatrics, Medical School, National and Kapodistrian University of Athens, “Aghia Sophia” Children’s Hospital, 115 27 Athens, GreeceFirst Department of Paediatrics, Medical School, National and Kapodistrian University of Athens, “Aghia Sophia” Children’s Hospital, 115 27 Athens, GreeceNeonatal Department, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, GreeceNeonatal Department, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece2nd Neonatal Intensive Care Unit, “Aghia Sophia” Children’s Hospital, 115 27 Athens, GreeceBlood Transfusion Department, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, GreeceNeonatal Department, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, GreeceNeonatal Department, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece<i>Background and Objectives</i>: congenital heart disease (CHD), cyanotic and, to a lesser degree, acyanotic, often are accompanied by coagulation abnormalities, impacting substantially morbidity and mortality. Until now, no consistent hemostatic patterns have been demonstrated in neonates and children with CHD because they represent a variable and heterogenous population. The aim of the present study is to investigate the hemostatic profile, as well as the role of ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin type-1 motives), the cleaving protein of von Willebrand factor (VWF) in neonates with CHD and compare them to healthy age-matched controls. <i>Materials and Methods</i>: twenty neonates with a mean gestational age of 37.1 ± 2.5 weeks were included in the CHD group, and 18 healthy neonates with a mean gestational age of 38.2 ± 1.5 weeks were in the control group. <i>Results:</i> prothrombin time was significantly prolonged, and accordingly, factor VII (FVII) levels were significantly decreased in the CHD group in comparison to controls. Factor VIII (FVIII), VWF, and ristocetin cofactor activity (Rcof) levels were significantly higher in the study vs. control group. Concentrations of ADAMTS-13 were decreased in the CHD vs. control group, but the difference was not statistically significant. Our results, in combination, indicate a balanced hemostatic mechanism, although with greater variability in neonates with CHD, while developmental aspects of coagulation are evident in the specific patient population. <i>Conclusions:</i> the coagulation profile is moderately impaired early in the course of CHD, though increased thrombogenicity is already present and should not be ignored.https://www.mdpi.com/1648-9144/60/2/268neonatescongenital heart diseasecoagulation abnormalitiesADAMTS-13 |
| spellingShingle | Paraskevi Papadogeorgou Serena Valsami Maria Boutsikou Eleni Pergantou Aimilia Mantzou Ioannis Papassotiriou Zoi Iliodromiti Rozeta Sokou Elena Bouza Marianna Politou Nicoletta Iacovidou Theodora Boutsikou Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot Study Medicina neonates congenital heart disease coagulation abnormalities ADAMTS-13 |
| title | Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot Study |
| title_full | Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot Study |
| title_fullStr | Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot Study |
| title_full_unstemmed | Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot Study |
| title_short | Coagulation Profile in Neonates with Congenital Heart Disease: A Pilot Study |
| title_sort | coagulation profile in neonates with congenital heart disease a pilot study |
| topic | neonates congenital heart disease coagulation abnormalities ADAMTS-13 |
| url | https://www.mdpi.com/1648-9144/60/2/268 |
| work_keys_str_mv | AT paraskevipapadogeorgou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT serenavalsami coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT mariaboutsikou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT elenipergantou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT aimiliamantzou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT ioannispapassotiriou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT zoiiliodromiti coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT rozetasokou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT elenabouza coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT mariannapolitou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT nicolettaiacovidou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy AT theodoraboutsikou coagulationprofileinneonateswithcongenitalheartdiseaseapilotstudy |